selurampanel

Selurampanel is an orally active, small molecule drug that acts as a competitive antagonist at the AMPA and kainate subtypes of ionotropic glutamate receptors. It is structurally related to the quinoxalinedione series and competes with glutamate for binding at these receptor sites. Selurampanel has been primarily developed for epilepsy, with additional investigation in migraine and other indications such as adrenocortical adenoma and endometrial stromal sarcoma. The drug demonstrates reasonable blood-brain barrier penetration and was under clinical development by Novartis, reaching up to phase 2 trials for epilepsy. Its mechanism of action involves blocking excitatory neurotransmission mediated by AMPA/kainate receptors, which may help control seizures in patients with epilepsy[1][3][4][5][8].

Other names

selurampanel